Results 21 to 30 of about 524 (148)
Clinical and Translational Science, 2023 Females present a higher risk of adverse drug reactions. Sex‐related differences in drug concentrations may contribute to these observations but they remain understudied given the underrepresentation of females in clinical trials.
Jessica Hindi +13 more
doaj +1 more source
Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates [PDF]
, 2021 Background: Allopurinol, an xanthine oxidase (XO) inhibitor, is a promising intervention that may provide neuroprotection for neonates with hypoxic-ischemic encephalopathy (HIE).
Bakkali, Loubna el +26 more
core +4 more sources
Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response [PDF]
, 2013 BACKGROUND Allopurinol is a main cause of severe cutaneous adverse reactions (SCAR). How allopurinol induces hypersensitivity remains unknown. Pre-disposing factors are the presence of the HLA-B*58:01 allele, renal failure and possibly the dose taken.
Mattsson, J, +6 more
core +2 more sources
Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats
Journal of Pharmaceutical Health Care and Sciences, 2022 Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and oxypurinol are potent XO inhibitors that reduce the plasma uric acid levels.
Yoshitaka Tayama +5 more
doaj +1 more source
Molecules, 2023 Due to the observed increase in the importance of computational methods in determining selected physicochemical parameters of biologically active compounds that are key to understanding their ADME/T profile, such as lipophilicity, there is a great need ...
Dawid Wardecki +2 more
doaj +1 more source
Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01
Scientific Reports, 2023 Allopurinol, widely used in gout treatment, is the most common cause of severe cutaneous adverse drug reactions. The risk of developing such life-threatening reactions is increased particularly for HLA-B*58:01 positive individuals.
Xuelu Huan +3 more
doaj +1 more source
Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects [PDF]
British Journal of Clinical Pharmacology, 1996 1 Eight healthy subjects received 50, 100, 300, 600 and 900 mg allopurinol daily for 1 week each, in random order with 1 week separating each treatment period. The pre‐dose plasma concentration of oxypurinol, the extent of inhibition of xanthine oxidase, plasma urate concentration and urine urate excretion rate were assessed on the last 2 days of each
S, Graham +6 more
openaire +2 more sources
Frontiers in Neurology, 2019 Background: Asphyxia is the most common cause of brain damage in newborns. Substantial evidence indicates that leukocyte recruitment in the cerebral vasculature during asphyxia contributes to this damage. We tested the hypothesis that superoxide radical (
Jacob B. Ruden +9 more
doaj +1 more source
Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism. [PDF]
PLoS ONE, 2017 Combination treatment with low-dose thiopurine and allopurinol (AP) has successfully been used in patients with inflammatory bowel disease with a so called skewed thiopurine metabolite profile.
Sofie Haglund +3 more
doaj +1 more source
Redox Biology, 2016 Upregulation of xanthine oxidoreductase (XOR) increases vascular reactive oxygen species (ROS) levels and contributes to nitroso-redox imbalance. However, XOR can generate nitric oxide (NO) from nitrite, and increased superoxide could inactivate NO ...
Gustavo H. Oliveira-Paula +7 more
doaj +1 more source